HARP.O
Latest Trade
20.00USDChange
-0.26(-1.28%)Volume
70,505Today's Range
-
20.5652 Week Range
-
25.23As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 20.26 |
|---|---|
Open | 20.56 |
Volume | 70,505 |
3M AVG Volume | 5.48 |
Today's High | 20.56 |
Today's Low | 19.41 |
52 Week High | 25.23 |
52 Week Low | 10.55 |
Shares Out (MIL) | 32.41 |
Market Cap (MIL) | 667.66 |
Forward P/E | -10.36 |
Dividend (Yield %) | -- |
Harpoon Therapeutics Reports Fourth Quarter And Full Year 2020 Financial Results And Provides Corporate Update
Harpoon Therapeutics Granted Orphan Drug Designation From FDA For Hpn217 For Treatment Of Multiple Myeloma
Harpoon Announces Closing Of Public Offering Of Common Stock
Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct, or TriTAC, platform, the Company is developing a pipeline of T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Its TriTAC product candidate, HPN424, is focused on the treatment of metastatic castration-resistant prostate cancer, or mCRPC.
Industry
Biotechnology & Drugs
Contact Info
131 Oyster Point Blvd Ste 300
SOUTH SAN FRANCISCO, CA
94080-1910
United States
+1.650.4437400
https://www.harpoontx.com/Executive Leadership
Ronald M. Hunt
Chairman of the Board
Gerald McMahon
President, Chief Executive Officer, Director
Georgia L. Erbez
Chief Financial Officer
Holger Wesche
Chief Scientific Officer
Christopher Whitmore
Vice President - Finance, Secretary
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 38.27 |
Price To Book (MRQ) | 9.78 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 0.00 |
LT Debt To Equity (MRQ) | 0.00 |
Return on Investment (TTM) | -35.94 |
Return on Equity (TTM) | -28.67 |
* HARPOON THERAPEUTICS ANNOUNCES CHANGES TO BOARD OF DIRECTORS
* HARPOON THERAPEUTICS PRESENTS INTERIM PHASE 1 DATA FROM AN ONGOING DOSE ESCALATION TRIAL FOR THE PSMA-TARGETING TRITAC® HPN424 AT THE ASCO20 VIRTUAL SCIENTIFIC PROGRAM
* HARPOON THERAPEUTICS TO PRESENT INTERIM CLINICAL DATA FOR TRITAC® HPN424 AT THE ASCO20 VIRTUAL SCIENTIFIC PROGRAM Source text for Eikon: Further company coverage:
* HARPOON THERAPEUTICS DOSES FIRST PATIENT WITH HPN217, A BCMA TARGETING TRITAC, FOR MULTIPLE MYELOMA Source text for Eikon: Further company coverage:
* HARPOON THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $250.0 MILLION - SEC FILING Source: (http://bit.ly/2w8qzx9) Further company coverage:
* HARPOON THERAPEUTICS REPORTS FOURTH QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.